drugset / Trial / NCT00412321
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
Timeline
- Start
- 2005-05
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 9 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 12 mg/kg | Intravenous |